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StrokeWe propose a statistical model for dissecting a multilocus genotypic value into its main (additive and
dominant) effects and epistatic effects between different loci in a case–control association study. The model
can discern four different kinds of epistasis, additive×additive, additive×dominant, dominant×additive, and
dominant×dominant interactions. To test each kind of epistasis, a χ2 test statistic was computed for a two by
two contingency table derived from combined genotypes in both case and control groups. We derived an
analytical approach for estimating the asymptotic distribution of the χ2 test statistic for epistatic tests under
the null hypothesis, with the result being consistent with that from Monte Carlo simulations. The new model
was used to analyze a case–control data set for candidate gene studies of stroke, leading to the identiﬁcation of
several signiﬁcant interactions between causal SNPs on this disease.u@bjfu.edu.cn (R. Wu).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.1. Introduction
The past two decades have witnessed an explosion of new
biotechnologies for generating high-throughput molecular marker
data. In a coupling of these technologies, the rapid development of
powerful statistical methods has made it possible for geneticists to
dissect a complex human disease into its underlying genetic
components. Despite signiﬁcant advances in the endeavor of
molecular dissection, however, our understanding of the genetic
architecture of a complex disease is still very limited. This may be
partially due to the fact that a disease or disorder often involves a
multi-factorial underpinning in which many genes contribute to the
expression of the disease. Yet, a vast body of evidence has shown that
the effects of some of these genes do not sum up in a simple additive
fashion rather than through interactions or epistasis [1–5]. Because of
epistasis, the presence of two or more particular genes may increase
or reduce the risk to a disease more than expected from their
independent effects.
With the increasing availability of genetic markers, especially
single nucleotide polymorphisms (SNPs), typed throughout the entire
genome, attempts to characterize the detailed genetic architecture of
a complex disease have been a routine procedure [6–8]. In so doing,
statistical methods for identifying a network of genetic interactions
and estimating genetic causes of epistasis are particularly needed.
There have been several methods for estimating epistasis using a
case–control design [9–11], although they do not offer a geneticinterpretation of epistasis. Depending on its formation mechanisms,
epistasis is partitioned into interactions between additive and
dominant effects at different loci [12–14]. The separation of each of
these components has proven essential to understand the genetic
architecture of a trait and further predict its phenotypic change.
In a recent study, Wang et al. [15] derived a general model for
detecting epistasis in a case–control study by dissecting a multilocus
genotypic value into its underlying components. However, they did
not provide a theoretical derivation for testing the statistical
signiﬁcance of each component in a case–control study. In this article,
we combine conventional statistical modeling of categorial data and
quantitative genetic principles within the case–control design
framework, and extend this new procedure to allow a genome-wide
search for the distribution and magnitude of additive and dominant
actions and epistatic interactions through the genome. More
importantly, we derived an analytical approach for estimating the
asymptotic distribution of the χ2 test statistic under the null
hypothesis, greatly facilitating the signiﬁcance test of epistasis. We
used the new model to characterize and test various genetic
components using a case–control data set for stroke candidate-gene
studies. The power of the model is studied through computer
simulation.
2. Model
2.1. Study design
Suppose there is a natural human population, from which two
groups of samples are drawn at random. One group includes m cases
who display a disease, and the second group includes n controls with
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potentially important covariates such as age, sex, ethnicity, geograph-
ical location, environmental factors, etc. All the cases and controls are
genotyped for two SNPs A (with two alleles A and a) and B (with two
alleles B and b). Three genotypes at each SNP are symbolized by 2 for
AA or BB, 1 for Aa or Bb, and 0 for aa or bb, respectively. Thus, joint
genotypes at these two SNPs are expressed as (2,1,0)⊗(2,1,0). Let
mj1 j2 and nj1 j2 be the observed numbers of genotypes j1 (j1=2,1,0) at
SNP A and j2 ( j2=2,1,0) at SNP B in cases and controls, respectively.
Thus, a (2×9) contingency table will be formed.
2.2. Test for the overall genetic effect
The ﬁrst test is about the association between overall genotypes
and disease. Let p and q denote the frequencies of subjects with
disease (cases) and without disease (controls) in the original
population so that we have
pˆ =
m
N
and qˆ =
n
N
; ð1Þ
with N=m+n. Let pj1j2 be the frequency of genotype j1j2 in the
overall population mixed with cases and controls. The estimate of the
genotype frequency in the overall population is obtained as
gˆj1 j2 =
mj1 j2 + nj1 j2
m + n
; j1; j2 = 0;1;2 : ð2Þ
Under the expectation that joint SNP genotypes are independent
of the disease, the frequency of genotype j1j2 in cases and controls can
be expressed as pj1 j2 = gˆj1 j2 pˆ and qj1 j2 = gˆj1 j2 qˆ. Thus, a χ
2 test statistic
for testing the SNP-disease association can be calculated by
χG2 = ∑
2
j1 =0
∑
2
j2 =0
mj1 j2−pj1 j2N
 2
pj1 j2N
+
nj1 j2−qj1 j2N
 2
qj1 j2N
2
64
3
75; ð3Þ
which follows a χ2-distribution with (9−1)(2−1)=8 degrees of
freedom. If χG2Nχdf=82 , this suggests that the two SNPs studied are
signiﬁcantly associated with the disease. Otherwise, there is no
signiﬁcant association between the two-SNP genotypes and the
disease.
2.3. Tests for epistatic effects
Several models have been proposed to characterize genetic
epistasis between different genes [12]. However, all these models
focus on epistasis estimation for the phenotypic values of genotypes
rather than their occurrences. By using a contingency table in a case–
control setting, we sought to incorporate traditional epistatic models
to deﬁne the effects of epistasis on the occurrences of genotypes. Here,
we use one of the most popular model, Mather and Jinks' [12], to
separate different epistatic components in a case–control study. For
two SNPs A and B, the Mather–Jinks model speciﬁes the genotypic
value (μj1j2;j1,j2=2,1,0) for the count of an arbitrary genotype in the
following way:
BB Bb bb
AA µ + a1 + a2 + iaa µ + a1 + d2 + iad µ + a1 − a2 − iaa
Aa µ + d1 + a2 + ida µ + d1 + d2 + idd µ + d1 − a2 − ida
aa µ − a1 + a2 − iaa µ − a1 + d2 − iad µ − a1 − a2 + iaa
ð4Þ
where μ = 14 μ 22 + μ 20 + μ 02 + μ 00ð Þ is the overall mean,
a1 =
1
4
μ 22−μ 00 + μ 20−μ 02ð Þ ð5Þis the additive genetic effect of SNP A,
a2 =
1
4
μ 02−μ00−μ 20 + μ 22ð Þ ð6Þ
is the additive genetic effect of SNP B,
d1 =
1
4
2μ 10−μ00−μ20−μ02−μ 22 + 2μ 12ð Þ ð7Þ
is the dominance genetic effect of SNP A,
d2 =
1
4
2μ 01−μ00−μ 20−μ02−μ22 + 2μ21ð Þ ð8Þ
is the dominance genetic effect of SNP B,
iaa =
1
4
μ22−μ20−μ02 + μ00ð Þ ð9Þ
is the additive×additive epistatic effect,
iad =
1
4
2μ21−μ22−2μ01 + μ00−μ20 + μ02ð Þ ð10Þ
is the additive×dominance epistatic effect,
ida =
1
4
2μ 12−2μ 10 + μ00 + μ20−μ02−μ22ð Þ ð11Þ
is the dominance×additive epistatic effect, and
idd =
1
4
4μ 11 + μ00 + μ20 + μ02 + μ 22−2μ 10−2μ 12−2μ01−2μ 21ð Þ
ð12Þ
is the dominance×dominance epistatic effect between the two SNPs.
Reformulating the original (2×9) contingency table for genotypic
counts according to epistatic partitioning (9)–(12), we have new
contingency tables as follows:
2µ + 2iaa 2µ − 2iaa
Cases m22 + m00 m20 + m02
Controls n22 + n00 n20 + n02
ð13Þ
for the additive×additive epistatic effect,
2µ + d2 + iad 2µ + d2 − iad
Cases m21 + 12m02 +
1
2m00 m01 +
1
2m20 +
1
2m22
Controls n21 + 12n02 +
1
2n00 n01 +
1
2n20 +
1
2n22
ð14Þ
for the additive×dominance epistatic effect,
2µ + d1 + ida 2µ + d1 − ida
Cases m12 + 12m20 +
1
2m00 m10 +
1
2m02 +
1
2m22
Controls n12 + 12n20 +
1
2n00 n10 +
1
2n02 +
1
2n22
ð15Þ
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2µ+ idd 2µ
Cases m11 + 14m00 +
1
4m02
1
2(m10 + m12
+ 14m20 +
1
4m22 + m01 + m21)
Controls n11 + 14n00 +
1
4n02
1
2(n10 + n12
+ 14n20 +
1
4n22 + n01 + n21)
ð16Þ
for the dominance×dominance epistatic effect.
χ2-test statistics are calculated for each of these epistatic
components, i.e., χiaa
2 , χiad
2 , χida
2 , and χidd
2 , based on tables (13), (14),
(15), and (16), respectively. Note that, in table (14)–(16), cell counts
are formed by a weighted combination of original observed cell
counts. Therefore, test statistics, χiad
2 , χida
2 , and χidd
2 , may not obey a χ2
distribution with one degree of freedom. We have proved that under
the null hypothesis, these test statistics are asymptotically smaller
thanχdf=12 (Appendix A). Thus, the use ofχdf=12 as a critical threshold
for these signiﬁcance tests is conservative. An empirical approach for
determining the threshold values of the corresponding signiﬁcance
tests is based on resampling methods, but this will be time
consuming. We derived an approximation approach for determining
the critical thresholds. In general, the asymptotic null distributions for
these epistatic interactions can be expressed as cadχdf=12 , cdaχdf=12 ,
and cddχdf=12 , respectively, with 0bcad,cda,cddb1 derived from the
models. These coefﬁcients can then be estimated using a two-moment
approximation approach (Appendix B). Table 1 gives the comparisons
of critical values derived from our approach and χdf=12 when different
minor-allele frequencies are assumed.
Similarly, the additive and dominancemain effects of the two SNPs
can also be tested by calculating test statistics χa1
2 , χd1
2 , χa2
2 , and χd2
2
from Eqs. (5), (6), (7), and (8), respectively. For the dominance
effects, we need to derive a two-moment approximation approach for
determining the critical threshold.
2.4. Corrections for multiple comparisons
When many pairs of SNPs are studied at the same time, an issue
naturally arises about the correction of multiple tests. One approach
for accounting for multiple comparisons is to use the Bonferroni
approach. This is often conservative, especially for dependent tests. ToTable 1
Critical values of test statistics χad2 , χda2 , and χdd2 at α levels of 0.05, 0.01, 0.001, 0.0001,
and 0.00001 under different minor allele frequencies (MAF) for a pair of SNPs.
MAF α 0.05 0.01 0.001 0.0001 0.00001
χdf=12 3.84 6.63 10.83 15.14 19.51
0.1/0.1 χad2 3.1549 5.3212 8.3337 10.97 12.751
χda2 3.1936 5.4368 8.4441 10.687 12.123
χdd2 1.6987 2.9595 4.7986 6.951 7.4992
0.1/0.3 χad2 2.7938 4.7896 8.1392 10.943 12.768
χda2 2.7837 4.8017 7.8063 10.246 14.959
χdd2 2.0123 3.4945 5.7514 7.7001 10.08
0.1/0.5 χad2 2.6998 4.5958 7.2216 9.7148 12.364
χda2 2.5157 4.3675 7.0457 9.2568 11.153
χdd2 2.1751 3.7064 6.029 8.5415 10.472
0.3/0.3 χad2 2.8816 5.0217 8.1456 11.842 15.147
χda2 2.8891 5.0263 8.1244 11.225 12.566
χdd2 2.3907 4.1797 6.7936 9.253 11.398
0.3/0.5 χad2 2.8735 4.962 8.0361 11.612 13.382
χda2 3.0778 5.2902 8.3141 11.625 13.354
χdd2 2.5 4.2851 7.0591 9.991 11.056
0.5/0.5 χad2 3.1683 5.4443 9.0419 12.861 15.207
χda2 3.2107 5.5233 9.0267 12.471 14.8
χdd2 2.4843 4.3424 7.0572 9.3762 11.909overcome this, other approaches based on the false recovery rate and
permutation or randomization tests can also be used [16].
3. Worked example
As part of the ongoing human genetic projects at the Genome
Institute of Singapore, a total of 830 unrelated stroke patients were
randomly sampled from a human population of a Chinese ancestry,
aimed to study the genetic association between SNPs and stroke. The
controls which are matched for age, ethnicity, and other demograph-
ical factors include 454 normal unrelated subjects. Standard methods
were used to collect blood and extract DNA from both cases and
controls. Previous studies identiﬁed 27 candidate genes for stroke,
located on chromosomes 1, 2, 5, 11, 14, 17, 18, and 21 [17]. From each
of these candidate genes, a panel of SNPs was genotyped. In this study,
we chose those tagging SNPs within each gene that together explains
80% or more genetic diversity of haplotypes. Our model does not rely
on the Hardy–Weinberg equilibrium assumption. A standard method
for case–control studies was used to perform single-locus association
analyses. Of all 306 SNPs, 14 were detected to be signiﬁcant before the
Bonferroni correction, but none of them remains signiﬁcant after
accounting for multiple comparisons.
We then used our new model to test the epistasis between each
pair of these selected 14 SNPs, identifying four pairs that produce
signiﬁcant epistatic interactions. These signiﬁcant pairs are two SNPs
rs16879248 and rs3822444 from gene MTRR on chromosome 5 and
two SNPs rs2357482 and rs8011839, two SNPs rs3818240 and
rs8011839, and two SNPs rs4902278 and rs8011839 from gene
MTHFD1 on chromosome 14. According to the association test, no two
SNPs on the same chromosome are in complex linkage disequilibria,
suggesting that each represents a different locus. By testing each kind
of epistasis individually, only a dominant×additive epistatic interac-
tion effect was detected to be signiﬁcant for each pair after the
correction for multiple comparisons (Table 2). The three other kinds
of epistasis were detected to be nonsigniﬁcant. The signiﬁcance level
of the dominant×additive epistasis, determined by a two-moment
approximation approach, is found to achieve p=1.25×10−6. The
same data were analyzed by a logistic regression model in which
additive and dominant effects of each SNP and four kinds of epistasis
between each pair of SNPs were included, producing similar results.
But the signiﬁcance levels were detected to decrease as compared
with the new epistatic model (Table 2).
4. Computer simulation
We performed simulation studies to investigate the power and
Type I errors of epistatic detection by the new model. The ﬁrst
simulation scheme includes 50 independent causal SNPs segregating
in 500 cases and 500 controls, from which two SNPs were assumed to
have a small main effect (odds ratio=1.2) and amoderate interaction
effect (odd ratio=1.4). For a pair of SNPs, a (2×9) contingency tableTable 2
Signiﬁcance tests for detecting the dominant×additive epistasis in a case–control
design by the epistatic model and the logistic regression with full model.
Chr. Gene SNP pair Epistatic Logistic
regression
HWD test
p-value
MAF
5 MTRR rs16879248 1.27×10−6 N.A. 0.04 0.22
vs. rs3822444 0.60 0.20
14 MTHFD1 rs2357482 1.25×10−6 2.37×10−3 0.29 0.37
vs. rs8011839 0.39 0.14
14 MTHFD1 rs3818240 1.25×10−6 2.37×10−3 0.33 0.32
vs. rs8011839 0.39 0.14
14 MTHFD1 rs4902278 1.25×10−6 2.37×10−3 0.25 0.37
vs. rs8011839 0.39 0.14
HWD = Hardy–Weinberg disequilibrium, MAF = minor allele frequency.
Fig. 1. The linkage disequilibrium structure for nine tagging SNPs simulated by
mimicking the segregation pattern of SNPs within gene MTHFD1 on chromosome 14.
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constraints test statistics χa1
2 , χd1
2 , χa2
2 , χd2
2 bχ0.052 and χiaa
2 , χiad
2 , χida
2 ,
χidd
2 Nχ0.052 . These test statistics were calculated from collapsed
contingency tables; for examples, tables (13)–(16) for four kinds of
epistasis. Then, a logistic model that considers all additive, dominant
and epistatic effects for nine 2-locus genotypes G1,…,G9, expressed as
Logit P y = 1 jG1;…;G9ð Þð Þ = μ j1 j2 ;
was used to simulate 500 cases and 500 controls.
We used both the new epistatic model and logistic regression
model to analyze the simulated data. A full model for logistic
regression is expressed as
Logit P y = 1ð Þð Þ = μ + a1x1 + a2x2 + d1z1 + d2z2 + iaax1x2
+ iadx1z2 + idaz1x2 + iddz1z2;
where xk and zk (k=1 for SNP 1 or 2 for SNP 2) are the indicator
variables that are deﬁned as
xk =
( 1; for genotype AA at SNP 1 or BB at SNP 2
0; for genotype Aa at SNP 1 or Bb at SNP 2
−1; for genotype aa at SNP 1 or bb at SNP 2;
zk =
1; for genotype Aa at SNP 1 or Bb at SNP 2
0; for genotype AA= aa at SNP 1 or BB= bb at SNP 2:

The epistatic model detects additive×additive effects with a
comparable power by the logistic regression model (Table 3).
However, for all other three kinds of epistasis, the former displays
reasonably high power, while the latter almost detects nothing. Also,
lower Type I errors were detected from the epistatic model. As
approved in the appendix, increased power obtained by the new
model may result from unequal contributions of different genotypes
to a new collapsed contingency table (see contingency tables (14),
(15) and (16) from original table (4)), which leads to a reduced
critical threshold for hypothesis tests.
The second simulation scheme produces multiple SNPs with linkage
disequilibria (LD) by mimicking the segregation pattern of 27 SNPs at
gene MTHFD1 on chromosome 14 collected in the above case–control
study of stroke. Using the Haploview software [18], we removed those
SNPs that have a high correlation (RN85%), leading to nine SNPs. Based
on the joint distribution of these nine SNPs, we simulated 500 cases and
500 controls. The simulated genotypes show similar LD structure to the
real data (Fig. 1). As in the ﬁrst simulation study, the data were
simulated by constraining small main effects and moderate interaction
effects for each pair of SNPs. The results from this simulation scheme
(Table 4) are consistent with those from the ﬁrst one.
Fig. 2 illustrates the power and false positive error rates of the
interaction detection between each pair of SNPs by the epistatic and
logistic regression models. It can be seen that the new epistatic model
outperforms substantially than the logistic regression model under
most circumstances for the additive×dominant, dominant×additive,
or dominant×dominant epistasis. The result from this simulationTable 3
Power and Type I error rate (TIE) for the epistatic detection of two independent SNPs by
the epistatic and logistic regression models.
Epitasis Epistatic Logistic
Power TIE Power TIE
Additive×additive 47 2 50 5
Additive×dominant 63 6 0 6
Dominant×additive 59 8 0 8
Dominant×dominant 35 4 0 7suggests that signiﬁcant epistatic effects detected in the stroke genetic
project above are likely to be biologically relevant.
5. Discussion
In this article, we present a model for dissecting a multilocus
genotypic value into its different components in a case–control study
via population-based sampling. This model allows the assessment of
interactive relationships between variation in a deﬁned genetic region
and a disease using multiple SNP genotypes collected on cases and
controls. By evaluating joint-SNP genotypes, rather than single-locus
tests of association, the loss of information attributable to multilocus
interactions can be overcome and possibly improved. Previous studies
have considered the effects of epistatic interactions on a complex
disease with a case–control design [9,10,11], but none of them
provides procedure for testing different components of epistasis
which may have played a different role in disease control.
Our model is based on the combination between conventional
categorical data analysis and quantitative genetic principle. Although
we implemented a χ2 test statistic approach to test the signiﬁcance of
epistasis, a number of other approaches, such as logistic regression,
odds ratio and G2 test statistic, can also be used for such tests. Each of
these approaches has their own advantages and disadvantages.
Compared to standard logistic regression in which cell frequencies
are modeled on a log-linear scale, our approach based on contingency
tables can increase computational efﬁciency by modeling cell frequen-
cies on a linear scale. Furthermore, results from simulation studies andTable 4
Power and Type I error rate for the epistatic detection of two associated SNPs by the
epistatic and logistic regression models.
Epitasis Epistatic Logistic
Power TIE Power TIE
Additive×additive 44 2 45 6
Additive×dominant 23 3 5 5
Dominant×additive 37 4 3 6
Dominant×dominant 16 3 4 10
Fig. 2. Comparison in power and Type I error rate for the epistatic detection of each pair from nine tagging SNPs by the epistatic and logistic regression models. (A) Additive×additive,
(B) Additive×dominant, (C) Dominant×additive, and (D) Dominant×dominant.
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the tests of the additive×dominant, dominant×additive, and dom-
inant×dominant epistasis than logistic regression.
Through theoretical derivations, we have identiﬁed a statistical
foundation for the increased power of our approach to detect the
additive×dominant, dominant×additive, and dominant×dominant
epistasis. It is found that tests of these three kinds of epistasis based on
weighted combinations of observed zygotic genotypes have smaller
critical thresholds than the χdf=12 value, although all these tests
contain one degree of freedom. We derived a two-moment approx-
imation approach for determining the critical values for these
epistatic tests. As demonstrated in simulation studies, our two-
moment approximation and correction strategy can minimize the
impact of the LD structure, but the statistical power will be hampered.
Therefore in principle, we recommend testing the epistasis effects
between pairs of SNPs with nonsigniﬁcant main effects and from
different LD blocks. When testing epistasis of SNPs with strong LD is
inevitable, and if it is computationally applicable, permutation tests or
large scale simulations still can be utilized.Themodel can be extended in the following aspects. First, our test is
based on joint SNP genotypes, but the effects of haplotypes on a disease
may be important [19,20] and can be modeled in a case–control design
by estimating haplotype frequencies within a mixture model frame-
work. Second, in the current model speciﬁcation, we choose controls
that are matched for cases in terms of biological, environmental, or
demographical factors. When such matches are not possible, we need
to embed these factors as covariates into the model, in which the
interactions between genes and these factors can be tested. Third, the
model can be extended with multiple diseases to consider the
pleiotropic effect of a gene. These extensions will represent a valuable
discovery tool for examining genomic function and clarifying patho-
physiological mechanisms. The MatLab source code and the R source
code are freely available at: http://statgen.psu.edu.
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150 T. Liu et al. / Genomics 98 (2011) 145–151Appendix A. Asymptotic distribution of χ2 test statistics
Testing the additive×dominant epistatic effect uses part of the
original (2×9) contingency table, i.e.,
AABB AABb AAbb aaBB aaBb aabb Sum
Cases m22 m21 m20 m02 m01 m00 mad..
Controls n22 n21 n20 n02 n01 n00 nad.. ,
(A1)
where cell counts are assumed to have a multinomial distribution
with cell probabilities π=(π221 ,…π001 , π222 ,…π002 )′. Let p=(p221 ,…p001 ,
p22
2 ,…p002 )′ denote the sample proportions, where pij1=mij/n..ad and
pij
2=nij/n..ad. By the multivariate central limit theorem ([21]), we have
ﬃﬃﬃﬃﬃﬃﬃﬃ
n ::
ad
q
p−πð Þ→d N 0;diag πð Þ−π π′ : ðA2Þ
Let g(⋅) be a function such that
g pð Þ =

p121 +
1
2
p102 +
1
2
p100; p
1
01 +
1
2
p120 +
1
2
p122;
p021 +
1
2
p002 +
1
2
p000; p
0
01 +
1
2
p020 +
1
2
p022

′
= pad11;p
ad
12;p
ad
21;p
ad
22
 
′ = pad
g πð Þ =

π121 +
1
2
π102 +
1
2
π100;π
1
01 +
1
2
π120 +
1
2
π122;
π021 +
1
2
π002 +
1
2
π000;π
0
01 +
1
2
π020 +
1
2
π022

′
= πad11;π
ad
12;π
ad
21;π
ad
22
 
′ = πad:
Let ϕi=∂g/∂πi (i=1,…n..ad) denote ϕi=∂g/∂ ti evaluated at t=π.
By the multivariate version of the delta method, we have
ﬃﬃﬃﬃﬃﬃﬃ
n ::
ad
q
g pð Þ−g πð Þ½ →d N 0;ϕ′ diag πð Þ−ππ′ ϕ : ðA3Þ
This can be simpliﬁed as
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n ::
ad
q
pad−πadð Þ→
d
N 0;diag πadð Þ−πadπ′ad−Wad
h i
; ðA4Þ
whereWad = − 14 diag π102 + π100;π120 + π122;π202 + π200;π220 + π222
 	
′.
Under the null hypothesisH0: πij=πi.π. j, πad ismodeled by πad=π(θ)
with θ=(π1.ad,π.1ad,π2.ad,π.2ad). Using the delta method ([22]), we haveﬃﬃﬃﬃﬃﬃﬃﬃ
n ::
ad
q
pad−πad
πˆad−πad

 
→
d
N 0;Σ
 	
; ðA5Þ
where
∑ =
∑1; ∑2;
∑3; ∑4
 !
;
∑1 = diag πadð Þ−πadπ′ad−Wad
∑2 = diag πadð Þ−πadπ′ad−Wad
h i
D′
∑3 = D diag πadð Þ−πadπ′ad−Wad
h i
∑4 = D diag πadð Þ−πadπ′ad−Wad
h i
D′
D = diag πadð Þ1=2A A′Að Þ−1A′diag πadð Þ−1=2
A = diag πadð Þ−1=2 ∂πad = ∂θ0ð Þ
and note that θ0 is the estimate of θ under the null hypothesis.The test statistic for testing the additive×dominant epistatic effect
is χiad
2 =eadead′, where ead=(e11ad, e12ad, e21ad, e22ad) are the residuals. Since
the residuals can be expressed as a function of pad and πˆad, using the
delta method, we obtain
ead→
d
N 0;∑
 	
; ðA6Þ
where
∑ = I−π1 = 2ad π
1 = 2
ad
′−A A′A
 	−1A′−diag wadij
πadij
 !
−diag πadð Þ−1A A′Að Þ−1A′Waddiag πadð Þ−1
−diag πadð Þ−1WadA A′Að Þ−1A′diag πadð Þ−1
−BWadB′
B = diag πadð Þ−1A A′Að Þ−1A′:
According to Rao [21], the quadratic form Xiad
2 =eadead′ has a χ2-
distribution if and only if ∑* * is idempotent. Clearly, χiad
2 =eadead′
does not have a χ2-distribution, since ∑**≠(∑**)2. Based on the
fact that∑0 = I−π
1 = 2
ad π
1 = 2
ad
′−A A′Að Þ−1A′ is idempotent ([22]) and
tr(∑0**)=1, we have
E X2iad
 
= E eadead′ð Þ = tr ∑ð Þbtr ∑0ð Þ = 1;
var X2iad
 
= var eadead′ð Þ = 2tr ∑ð Þ2
b2tr ∑0ð Þ2 = 2:
ðA7Þ
It is concluded that under the null hypothesis, χiad
2 is smaller and
more stable than χ12. Since ead is normally distributed, the quadratic
form χiad
2 =eadead′ can be expressed as
eadead′ = ∑
d
i=1
λi·z
2
i ; ðA8Þ
where λi are the nonzero eigenvalues of Σ** and zi2∼N(0,1) are
independent. This result comes directly from the statistical literature
(see [23]; p. 153). Similar arguments are also true for χiad
2 and χidd
2 .
Appendix B. Deriving critical thresholds
Based on Eq. (A8), we use two relatively simple but widely used
approximations to re-scale and adjust the test statistics. The ﬁrst
approximation, χad. adj2 =χiad
2 /c, is to re-scale χiad
2 to i12. According to the
properties of a χ2-distribution, E(χad. adj2 )=1. Thus, this simple re-
scaling is equivalent to a mean correction. Also, we can use a more
sophisticated correction to approximate the distribution of χiad
2 by
a·χb2, where a and b are determined by matching the ﬁrst two
moments of χiad
2 with those of a·χb2. A straightforward calculation
using Eq. (A7) yields the consistent estimators of a, b, and c:
aˆ =
tr ∑ˆ
 2
tr ∑ˆ
  ;
bˆ =
tr ∑ˆ
 h i2
tr ∑ˆ
 2 ;
cˆ = tr ∑ˆ
 
:
ðB1Þ
Although we can directly estimate the correction factors a, b, and c
explicitly using Eq. (B1) for each SNP pair separately, a common
correction for all SNP pairs is more desirable. Summary statistics
151T. Liu et al. / Genomics 98 (2011) 145–151across all SNP pairs are used to estimate the common value of a, b, and
c. This can be expressed as follows:
aˆcommon =
var χ2iad
 
2·χ2iad
;
bˆcommon =
2 ·χ2iad
h i2
var χ2iad
  ;
cˆcommon = χ
2
iad
:
ðB2Þ
Moreappropriately,we canuse robust estimators suchas the trimmed
mean and trimmed variance from an α-trimmed sample to replace the
corresponding terms in (B2) to achieve the robust estimators of acommon,
bcommonand ccommon. Basedonsimulationstudiesabout theperformanceof
the approximation using common corrections (B2), it is observed that our
approximation strategy provides adequately high detecting power and
restrain Type I errors at a low level. Another advantage of using a common
correction is that we can effectively use the genome to compensate the
inﬂation of the test statistics resulting from the LD structure.
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